Clinical trials: Nonalcoholic Steatohepatitis
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
NAFLD Among Patients With Type 2 Diabetes and CKD
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases, Type2 Diabetes
- Trial name
- NCT03826381
- Testing
- Magnetic resonance (MR) spectroscopy of the liver, Fibroscan, Continuous glucose monitoring (CGM) for four days.
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Liver Disease
Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
Non-alcoholic steatohepatitis represents 10 - 15% total cases of hepatic cirrhosis. In the upcoming years, the economic burden of this disease will increase and will mean an important problem for our health system due to obesity…
- Trial name
- NCT01650181
- Testing
- Metformin, Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Obesity
Mitochondrial Metabolism and Hepatic Complications of Obesity
The study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis.
- Trial name
- DMSO (NCT03302481)
- Testing
- liver biopsy
- Sponsor
- Nantes University Hospital
NAFLD
Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation
A. BACKGROUND Accumulation of fat in the liver due to non-alcoholic causes (NAFLD) is associated with hepatic insulin resistance, which impairs the ability of insulin to inhibit the production of glucose and VLDL .
- Trial name
- NCT02133144
- Testing
- overeating fat, overeating carbohydrate
- Where
- Finland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Helsinki
Non-alcoholic Fatty Liver Disease
Semaglutide in Nonalcoholic Fatty Liver Disease
The goal of this clinical trial is to test the therapeutic effect of Semaglutide in NAFLD and its sequelae in obesity and/or type 2 diabetes mellitus.
- Trial name
- NCT05813249
- Testing
- Rybelsus Oral Product, Ozempic Injectable Product, Tocopherol and/or Actos
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Zagazig University
NASH - Nonalcoholic Steatohepatitis
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment
- Trial name
- NCT04321343
- Testing
- PXL065
- Where
- 29 sites in United States
- Volunteers
- 117 people
- Sponsor
- Poxel SA
Obesity, Obesity, Abdominal
Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD
This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in…
- Conditions
- Obesity, Obesity, Abdominal, NAFLD
- Trial name
- BRAVO (NCT05647915)
- Testing
- Berberine plus lifestyle intervention
- Where
- China
- Volunteers
- 337 people
- Sponsor
- China National Center for Cardiovascular Diseases
NAFLD
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
- Trial name
- NCT04634643
- Testing
- Usual diet and physical activity
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Yale University
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis
In a retrospective study, 200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fatty liver fibrosis have been identified for pathological diagnosis of liver histology and exclusion of other liver…
- Trial name
- NCT03842748
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Patients With Nonalcoholic Steatohepatitis
Evaluate the Efficacy, Safety and Tolerability of Fecal Microbiota Transfer for the Treatment of Patients With Nonalcoholic Steatohepatitis
The EMOTION study is a multicentric, double-blind, controlled, parallel-group, phase IIa randomized Clinical trial to evaluate the efficacy, safety and tolerability of TMF capsules for the treatment of patients with NASH.
- Trial name
- EMOTION (NCT05622526)
- Testing
- Group 1 or Experimental group, Group 2 or Control group
- Volunteers
- 96 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Fatty Liver Disease
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
Non-alcoholic fatty liver disease (NAFLD) has become a major health problem worldwide with an increasing prevalence ranging from 13% in Africa to 42% in South-East Asia.
- Trial name
- Fatty liver (NCT05694923)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Egypt
- Volunteers
- 55 people
- Sponsor
- Assiut University
Diabetes Mellitus, Non-alcoholic Fatty Liver Disease
Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD
Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat is deposited in the liver. Almost all patients also have obesity and insulin resistance (the inability of the body to effectively use insulin).
- Trial name
- FMT (NCT02496390)
- Testing
- Autologous, Allogeneic
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-alcoholic Fatty Liver Disease
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD)
This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for non-alcoholic fatty liver disease.
- Trial name
- NCT06225713
- Testing
- focused power ultrasound mediated inferior perirenal adipose tissue modification
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NASH - Nonalcoholic Steatohepatitis
Statins for the Treatment of NASH
The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.
- Trial name
- STAT NASH (NCT04679376)
- Testing
- Atorvastatin
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD.
- Trial name
- NCT04944992
- Testing
- Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
- Where
- 69 sites in United States, Argentina and 14 more
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonalcoholic Steatohepatitis
Betaine in Patients With Nonalcoholic Steatohepatitis
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
- Trial name
- NCT00586911
- Testing
- Cystadane
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Non-Alcoholic Steatohepatitis (NASH)
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
- Trial name
- IMPACT (NCT05989711)
- Testing
- Pemvidutide
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Altimmune, Inc.
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Metabolic Associated Fatty Liver Disease, Pancreatic Steatosis
Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients
This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatment naive or on treatment with…
- Conditions
- Metabolic Associated Fatty Liver Disease, Pancreatic Steatosis, Obese, Lean
- Trial name
- NCT07175688
- Testing
- Abdominal Ultrasound, Transient elastography, Waist Circumference
- Where
- Egypt
- Volunteers
- 217 people
- Sponsor
- Tanta University
NAFLD, NASH With Fibrosis
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
- Conditions
- NAFLD, NASH With Fibrosis, Liver Fibrosis
- Trial name
- NCT05506488
- Testing
- Dasatinib 100 MG + Quercetin (1000 MG)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.